Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...

An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.

Most of my life I have been pretty stoic about getting injections or blood draws and even as a child I wasn’t bothered by syringes or needles. Now the thought ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Phesgo is the combined therapy of Perjeta, Herceptin and ENHANZE, which is given in a single seven-minute subcutaneous injection for the treatment of breast cancer. We believe Phesgo is an ...

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a ...

In some cases, a painless injection is all that is now needed ... many as five biosimilars competing with Genentech’s biologic Herceptin, which treats early-stage breast cancer.